← Back to Search

Stem Cell Therapy

Mesenchymal Stem Cells for Respiratory Distress Syndrome

Phase 1
Waitlist Available
Led By Amanda L. Olson, MD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 7 days and 30 days
Awards & highlights

Study Summary

The goal of this clinical research study is to learn about the safety of giving mesenchymal stem cells (MSCs) to patients who have ARDS. Researchers also want to learn if these cells can help control ARDS when given with drugs that are routinely used to treat ARDS. In this study, participants will receive 1 infusion of MSCs. This is an investigational study. MSC infusions for the treatment of ARDS is investigational. Up to 20 patients will take part in this study. All will be enrolled at MD Anderson.

Eligible Conditions
  • Bone Marrow Transplant
  • Respiratory Distress Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 7 days and 30 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 7 days and 30 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Respiratory Distress Syndrome, Newborn
Secondary outcome measures
Clinical Improvement of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)
Improvement in PF or S/F Ratio of Participants Treated with Allogeneic Human Mesenchymal Stem Cells (hMSCs) With Acute Respiratory Distress Syndrome (ARD)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Mesenchymal Stem CellsExperimental Treatment1 Intervention
Participants receive Mesenchymal Stem Cells (MSCs) for adult respiratory distress syndrome (ARDS). Participants receive a maximum dose of 3 x 10^6 cell/Kg by vein one time on Day 1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mesenchymal Stem Cells (MSCs)
2017
Completed Phase 2
~50

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,986 Previous Clinical Trials
1,789,582 Total Patients Enrolled
1 Trials studying Respiratory Distress Syndrome
70 Patients Enrolled for Respiratory Distress Syndrome
Katz FoundationUNKNOWN
Amanda L. Olson, MDPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
5 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies
2017. "Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02804945.
~2 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top